What is the target trough tacrolimus level for patients with focal segmental glomerulosclerosis?

Target Trough Tacrolimus Level in FSGS

For patients with focal segmental glomerulosclerosis (FSGS), target tacrolimus trough levels of 5-10 ng/mL, with most evidence supporting the narrower range of 5-7 ng/mL.

Evidence-Based Recommendation

The 2021 KDIGO guideline for glomerular diseases explicitly recommends tacrolimus target trough levels of 5-10 ng/mL for FSGS 1. This represents the most authoritative and recent guidance available.

Supporting Guideline Evidence

The Canadian Society of Nephrology (2014) commentary on KDIGO guidelines specifically suggests tacrolimus levels of 5-7 ng/mL for steroid-resistant nephrotic syndrome (SRNS), which includes FSGS 2. This recommendation was based on levels achieved in clinical trials demonstrating efficacy, particularly the Gulati trial referenced in their commentary.

Dosing Strategy

• Starting dose: 0.05-0.1 mg/kg/day in two divided doses 1
• Target trough: 5-10 ng/mL (with 5-7 ng/mL being the more conservative and commonly cited range)
• Duration to assess efficacy: Continue for at least 4-6 months before declaring treatment failure 1
• Total treatment duration: At least 12 months for responders, with gradual taper over 6-12 months 1

Clinical Research Supporting These Levels

Multiple clinical studies support these target ranges:

• Pediatric studies consistently used target levels of 5-10 ng/mL 3, 4 or 7-15 ng/mL 5, with the 5-10 ng/mL range showing efficacy rates of 84-94% for achieving remission
• Adult studies targeted 5-10 ng/mL 6, 7, achieving complete or partial remission in 52-85% of patients

Important Caveats

Balancing Efficacy and Toxicity

The KDIGO guideline acknowledges that optimal CNI targets for glomerular diseases are not definitively established 1. The most reasonable approach is to:

1. Titrate to clinical effect on proteinuria rather than rigidly adhering to trough levels
2. Monitor serum creatinine closely - reduce dose if creatinine increases >30% from baseline
3. Discontinue if creatinine doesn't fall after dose reduction 1

Monitoring Requirements

• Check trough levels primarily to verify adherence and avoid toxicity 1
• Monitor serum creatinine monthly to detect nephrotoxicity early
• Assess for hyperglycemia - tacrolimus carries significant diabetogenic risk (26.7% in one study) 7

Population Considerations

The evidence base predominantly includes:

• Steroid-resistant FSGS patients - most studies enrolled patients who failed corticosteroids
• Both pediatric and adult populations show similar target ranges
• Primary FSGS - these targets apply to idiopathic disease, not genetic or secondary forms

Practical Algorithm

1. Start tacrolimus at 0.05-0.1 mg/kg/day divided twice daily
2. Target trough of 5-7 ng/mL initially (can extend to 10 ng/mL if needed for efficacy)
3. Monitor creatinine - if rises >30%, reduce dose to achieve lower trough (3-6 ng/mL)
4. Assess response at 4-6 months - continue if partial or complete remission achieved
5. Maintain for 12 months total, then taper gradually over 6-12 months

This approach prioritizes achieving remission (which improves long-term kidney survival) while minimizing nephrotoxicity and other adverse effects that compromise quality of life.